Showing 2141-2150 of 4063 results for "".
- Outlook Therapeutics Closes $55 Million Financing; Extends Cash Runway Through Anticipated FDA Approval of ONS-5010https://modernod.com/news/outlook-therapeutics-closes-55-million-financing-extends-cash-runway-through-anticipated-fda-approval-of-ons-5010/2481313/Outlook Therapeutics announced it closed on approximately $25 million registered direct equity offering, and about $30 million net proceeds from issuance of an unsecured convertible promissory note with an initial conversion price of $2. The $50 million net proc
- FDA Outlines Faster Path for COVID-19 Vaccines That Tackle New Variantshttps://modernod.com/news/fda-outlines-faster-path-for-covid-19-vaccines-that-tackle-new-variants/2478898/The FDA on Monday issued new guidance confirming that drugmakers will not have to perform large-scale trials for new COVID-19 vaccines or booster shots developed to combat new variants of SARS-CoV-2. “At this time, available information suggests that the FDA-authorized vaccines remain effec
- Zenni Releases New Anti-Fog Glasses Lenses to Address Mask-Related Fogginghttps://modernod.com/news/zenni-releases-new-anti-fog-glasses-lenses-to-address-mask-related-fogging/2478797/Zenni announced a 2-in-1 anti-fog + anti-reflective lens solution to solve a pain point for glasses wearers during the pandemic. Developed in 2020 as a response to the pervasive consumer issue of glasses fogging up while wearing face coverings, these new anti-fog coated lenses are the only low pr
- AGTC Announces Publication of Preclinical Data that Support the Ongoing Clinical Development of Its XLRP Gene Therapy Programhttps://modernod.com/news/agtc-announces-publication-of-preclinical-data-that-support-the-ongoing-clinical-development-of-its-xlrp-gene-therapy-program/2478200/Applied Genetic Technologies Corporation (AGTC) announced that preclinical data validating the transgene (hRPGRco) that is being evaluated in the company’s ongoing phase 1/2 clinical trial in patients with X-lined retinitis pigmentosa (XLRP) have been published in the July 15, 2020 print issue of
- Regeneron’s Novel COVID-19 Antibody Program Has Potential to Enter Human Clinical Studies by Early Summerhttps://modernod.com/news/regenerons-novel-covid-19-antibody-program-has-potential-to-enter-human-clinical-studies-by-early-summer/2477404/Regeneron Pharmaceuticals announced the latest progress in its efforts to discover and develop a novel multi-antibody cocktail that can be administered as prophylaxis before exposure to the SARS-CoV-2 virus or as treatment for those already infected. Regeneron scientists have now isolated
- Kowa Initiates Phase 3 Safety Trial for Glaucoma Drug Candidate NCX 470 in Japanhttps://modernod.com/news/kowa-initiates-phase-3-safety-trial-for-glaucoma-drug-candidate-ncx-470-in-japan/2482918/Nicox announced that its exclusive Japanese partner, Kowa, has officially initiated a phase 3 safety clinical trial for NCX 470 (also referred to as K-911) in Japan. NCX 470 is Nicox’s lead clinical candidate, currently undergoing phase 3 clinical evaluations
- Alcon Announces US Launch of Tryptyr for Dry Eye Diseasehttps://modernod.com/news/alcon-announces-us-launch-of-tryptyr-for-dry-eye-disease/2482908/Alcon announced the US commercial availability of Tryptyr (acoltremon ophthalmic solution) 0.003% for the treatment of the signs and symptoms of dry eye disease (DED). Approved by the FDA in May, eye care professionals (ECPs) across the US can officially begin p
- FDA Accepts Aldeyra's NDA for Reproxalap in Dry Eye Disease; Expands Partnership with AbbViehttps://modernod.com/news/fda-accepts-aldeyras-nda-for-reproxalap-in-dry-eye-disease/2482547/Aldeyra Therapeutics announced that the FDA has officially accepted for review the resubmitted new drug application (NDA) for its topical ocular therapy, reproxalap, aimed at treating the signs and symptoms of dry eye disease. The FDA has set a Prescription Drug User Fee Act (PDUFA) target d
- After Shortage, Harrow Announces Relaunch of Triesencehttps://modernod.com/news/after-shortage-harrow-announces-relaunch-of-triesence/2482468/Harrow has officially relaunched Triesence (triamcinolone acetonide injectable suspension) 40 mg/mL, a preservative-free synthetic corticosteroid. Triesence is approved by the FDA for use in visualizing tissues during vitrectomy and treating ocular inflammatory conditions that do n
- Former Regenxbio Execs Announce Launch of Gene Therapy Company Tern Therapeuticshttps://modernod.com/news/former-regenxbio-execs-announce-launch-of-gene-therapy-company-turn-therapeutics/2482414/Tern Therapeutics announced its official launch alongside the successful closing of a $15 million financing round. Simultaneously, Tern revealed a global licensing agreement with Regenxbio to acquire two gene therapy programs—RGX-381 and RGX-181—now designated as TTX-381 and